BR112023001563A2 - Composições e métodos para vacinação melhorada - Google Patents

Composições e métodos para vacinação melhorada

Info

Publication number
BR112023001563A2
BR112023001563A2 BR112023001563A BR112023001563A BR112023001563A2 BR 112023001563 A2 BR112023001563 A2 BR 112023001563A2 BR 112023001563 A BR112023001563 A BR 112023001563A BR 112023001563 A BR112023001563 A BR 112023001563A BR 112023001563 A2 BR112023001563 A2 BR 112023001563A2
Authority
BR
Brazil
Prior art keywords
compositions
orf
ops
methods
mirna
Prior art date
Application number
BR112023001563A
Other languages
English (en)
Inventor
Romain Micol
Valerie Duval
Original Assignee
Combined Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/019028 external-priority patent/WO2021168405A1/en
Application filed by Combined Therapeutics Inc filed Critical Combined Therapeutics Inc
Publication of BR112023001563A2 publication Critical patent/BR112023001563A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composições e métodos para vacinação melhorada. a presente invenção refere-se a uma composição compreendendo um primeiro construto de mrna compreendendo um primeiro quadro de leitura aberta (orf), em que o primeiro orf codifica um antígeno; em que o primeiro orf está operativamente ligado a pelo menos uma região não traduzida (utr), em que a utr compreende pelo menos uma primeira sequência de proteção de órgão (ops) e em que a primeira ops compreende pelo menos duas sequências-alvo de micro-rna (mirna), em que cada uma das pelo menos duas sequências-alvo de mirna são otimizadas para hibridar com uma sequência de mirna correspondente. também são fornecidas outras composições compreendendo construtos de mrna compreendendo um orf e uma ops em que o orf codifica uma citocina pró-inflamatória e métodos incluindo uma ou ambas as composições para o tratamento e prevenção de doenças, como doenças patogênicas.
BR112023001563A 2020-07-31 2021-07-30 Composições e métodos para vacinação melhorada BR112023001563A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059458P 2020-07-31 2020-07-31
PCT/US2021/019028 WO2021168405A1 (en) 2020-02-21 2021-02-22 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
PCT/US2021/043975 WO2022035621A1 (en) 2020-07-31 2021-07-30 Compositions and methods for improved vaccination

Publications (1)

Publication Number Publication Date
BR112023001563A2 true BR112023001563A2 (pt) 2023-10-10

Family

ID=80248099

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001563A BR112023001563A2 (pt) 2020-07-31 2021-07-30 Composições e métodos para vacinação melhorada

Country Status (11)

Country Link
US (1) US20240024451A1 (pt)
EP (1) EP4188393A1 (pt)
JP (1) JP2023536844A (pt)
KR (1) KR20230083266A (pt)
CN (1) CN116209771A (pt)
AU (1) AU2021326420A1 (pt)
BR (1) BR112023001563A2 (pt)
CA (1) CA3187345A1 (pt)
IL (1) IL300247A (pt)
MX (1) MX2023001187A (pt)
WO (1) WO2022035621A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117821482B (zh) * 2024-03-05 2024-06-18 中国人民解放军军事科学院军事医学研究院 一种编码猴痘病毒和新冠病毒融合抗原的mRNA疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US20170202979A1 (en) 2014-07-17 2017-07-20 Modernatx, Inc. Terminal modifications of polynucleotides
PT3408382T (pt) 2016-01-27 2022-06-27 Oncorus Inc Vetores virais oncolíticos e seus usos
EP3558356A2 (en) * 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3755344A1 (en) 2018-02-19 2020-12-30 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Also Published As

Publication number Publication date
EP4188393A1 (en) 2023-06-07
CA3187345A1 (en) 2022-02-17
KR20230083266A (ko) 2023-06-09
US20240024451A1 (en) 2024-01-25
MX2023001187A (es) 2023-04-04
AU2021326420A1 (en) 2023-03-09
JP2023536844A (ja) 2023-08-30
CN116209771A (zh) 2023-06-02
WO2022035621A1 (en) 2022-02-17
IL300247A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
BR112022015053A2 (pt) Composições imunizantes contra vírus respiratórios
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0821286A8 (pt) Métodos e composições para imunizar porcos contra circovirus suino
BR112017024331A2 (pt) composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112014018432A8 (pt) Proteína, composição imunogênica, método para produzir proteína e para tratar ou prevenir doença, molécula de ácido nucleico, vetor, célula hospedeira, uso de uma proteína, e, uso de uma composição imunogênica
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112022001341A2 (pt) Inibidores de enzima
CL2021001490A1 (es) Constructos de iarn modificados químicamente y usos de estos
CU23632A1 (es) Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
BR112022024501A2 (pt) Construtos de rnai para inibir a expressão de hsd17b13 e métodos de uso dos mesmos
BR112023001563A2 (pt) Composições e métodos para vacinação melhorada
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
ECSP23096498A (es) Restos de administración terapéutica novedosos y usos de estos
ZA202208795B (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
CL2021001489A1 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
BR112021024080A2 (pt) Construtos de rnai para inibir a expressão de scap e métodos de uso dos mesmos
DOP2022000218A (es) Anticuerpos anti-phf-tau y usos de estos
BR112022024156A2 (pt) Compostos heterocílicos antelmínticos
UY39699A (es) Anticuerpos anti-tau y usos de estos
BR112021014640A8 (pt) Sais de sulcardina